Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

How safe are very low LDL cholesterol levels?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 306–307 (2006)Cite this article

boxed-textWiviott SD et al.; PROVE IT-TIMI 22 Investigators (2005) Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 46: 1411–1416

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cannon CP et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504

    Article  CAS  Google Scholar 

  2. Pitt B (2005) Low-density lipoprotein cholesterol in patients with stable coronary heart disease—is it time to shift our goals? N Engl J Med 352: 1483–1484

    Article  CAS  Google Scholar 

  3. LaRosa JC et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435

    Article  CAS  Google Scholar 

  4. Cholesterol Treatment Trialists' (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278

  5. de Lemos JA et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292: 1307–1316

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. fellow in Cardiology,

    Sarkis B Baghdasarian & Paul D Thompson

  2. Chief of Cardiology and Director of Preventative Cardiology at the Hartford Hospital, University of Connecticut School of Medicine, Hartford, CT, USA

    Sarkis B Baghdasarian & Paul D Thompson

Authors
  1. Sarkis B Baghdasarian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul D Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul D Thompson.

Ethics declarations

Competing interests

PD Thompson acknowledges: research support from Merck, Pfizer, and AstraZeneca; consultancy for AstraZeneca; speaking honoraria from Merck, Pfizer, KOS, AstraZeneca and Schering Plough; and stock ownership in Pfizer, Merck and Schering Plough.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baghdasarian, S., Thompson, P. How safe are very low LDL cholesterol levels?. Nat Rev Cardiol 3, 306–307 (2006). https://doi.org/10.1038/ncpcardio0557

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0557

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing